Unexpected link between gene in liver and iron overload

December 06, 2005

A new study in the December Cell Metabolism reveals an unexpected connection between a tumor suppressor gene in the liver and the normally careful control over the amount of iron absorbed from the diet. The surprising finding demonstrates a critical role for the liver in iron metabolism. The discovery also suggests a new avenue for the treatment of hereditary hemochromatosis, an iron-overload disease that is one of the most common genetic disorders among Caucasians, according to researchers.

Chu-Xia Deng, from the National Institute of Diabetes and Digestive and Kidney Diseases, and his colleagues report that mice lacking the SMAD4 gene in the liver only suffer from a toxic buildup of iron, particularly in their liver, kidneys, and pancreas--symptoms similar to those exhibited by humans with hemochromatosis. In other respects, the animals appeared remarkably normal, the researchers found.

"Unexpectedly, the liver-specific knockout of SMAD4 does not have a major impact on liver development; instead it results in a dramatic accumulation of iron in the liver of mutant mice," Deng said. "In addition, several other organs with intact SMAD4, including pancreas, kidney, eye, and brain, also exhibit accumulation of iron starting from 2 months of age.

"Our work not only creates a new animal model for the study of hemochromatosis but also clearly indicates that the liver is a physiological center for regulation of iron homeostasis," he added.

Iron is an essential nutrient found in many foods, particularly in red meat and iron-fortified bread and cereal. In the body, iron becomes part of hemoglobin, a molecule in the blood that transports oxygen from the lungs to all body tissues. Iron deficiency results in anemia, whereas iron overload leads to organ and tissue damage.

Symptoms of hemochromatosis, the most common iron-overload disease, can include bronzed skin, enlarged liver, diabetes, and abnormalities of the pancreas and joints. Frequent removal of blood in the same manner applied to blood donors can lower iron levels and alleviate the symptoms. Without treatment, the disease can lead to organ failure.

In the current study, the researchers set out to explore SMAD4's role in liver development and maintenance, by creating mice with normal levels of the gene in all part of the body except the liver. A member of a critical cell signaling pathway known as the transforming growth factor ß (TGF-ß) superfamily, SMAD 4 plays many central roles in development.

Earlier studies had also linked abnormalities in SMAD4 to multiple forms of cancer. For example, mutations in the tumor suppressor gene are frequently detected in pancreatic cancer, colon cancer, and a common form of lung cancer called adenocarcinoma, Deng said.

"Yet we didn't see cancer in the mice and saw only minor defects in the liver," Deng said. "Still, the mice were sick with apparent problems in their pancreas and other organs. Initially, we had no information to suggest that the gene might play a role in iron balance."

The mice gradually lost weight, and more than half developed other signs of illness, including rough-looking fur, loss of muscle mass, and slower movement, by 10 months of age, the researchers reported. Many of the animals died at this stage, they said. Autopsy revealed that the animals had developed a dark red pancreas and brownish pigment deposition in multiple organs, including the liver and parts of the kidneys.

After extensive analysis, the team detected a significant overload of iron in tissue samples taken from the mutant mice. After reaching 2 months of age, the animals accumulated iron in the organs that had appeared abnormal, they reported.

To find out why the liver defect caused widespread iron accumulation, the team examined the activity of other genes previously found to play a role in iron metabolism. Mice lacking SMAD4 in the liver showed an approximately 100-fold decline in expression of hepcidin, an essential gene that limits iron absorption.

Hepcidin secreted from the liver into the bloodstream is known to curb iron intake in the intestine and prevent the release of iron from cells in the blood, the researchers said.

In the absence of hepcidin, other genes responsible for iron absorption in the intestine rose, the group found. Additional examination revealed that SMAD4 normally plays a direct role in increasing hepcidin activity.

A lack of hepcidin has been associated with iron overload, whereas excess hepcidin results in iron-deficiency anemia in mice, the researchers said. Furthermore, they added, people with two mutant copies of the gene suffer from severe juvenile hemochromatosis.

The findings, therefore, have potential significance for the treatment of iron overload, Deng said.

"Several genes cause hemochromatosis, but in all cases, hepcidin levels are down," he said. "Our findings suggest that drugs that boost the TGF- ß signaling pathway, either through SMAD4 or other members of the pathway, hold promise for treatment."
The researchers included Rui-Hong Wang, Cuiling Li, Xiaoling Xu, Yin Zheng, Cuiying Xiao, and Chu-Xia Deng of the National Institute of Diabetes and Digestive and Kidney Diseases in Bethesda, MD; Patricia Zerfas and Michael Eckhaus of the National Institutes of Health in Bethesda, MD; Sharon Cooperman and Tracey Rouault of the National Institute of Child Health and Human Development in Bethesda, MA; Lopa Mishra of Georgetown University in Washington, DC. This research was supported by the Intramural Research Program of the Institute of Digestive and Kidney Diseases, National Institutes of Health.

Wang at al.: "A role of SMAD4 in iron metabolism through the positive regulation of hepcidin expression." Publishing in Cell Metabolism, Vol. 2; Issue: 6; December 2005, pages 399-409. DOI 10.1016/j.cmet.2005.10.010 www.cellmetabolism.org

Cell Press

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.